SurvodutideSurvodutide
MedChemExpress (MCE)
HY-P4146
2805997-46-8
BI 456906
99.83%
Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture and light)
Room temperature in continental US
may vary elsewhere.
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
The EC50 is 0.36 nM for Survodutide (BI 456906) in the endogenous mouse GLP-1R in the insulinoma cell line MIN6, and the EC50 is 60 pM for GLP-1. In 0.5% human and mouse plasma, Survodutide shows a similar potency to that of endogenous GLP-1. For the GCGR, in 0.5% human and mouse plasma, Survodutide is 6-fold less potent (0.29 and 0.17 nM, respectively) in relation to endogenous glucagon (47 and 30 pM, respectively)[1]. Proteolytic stability of Survodutide is helped by C-terminal amidation and the introduction of a non-coded amino acid 1-aminocyclobutane-1-carboxylic acid (Ac4c) in position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4. The desired extended terminal half-life of Survodutide is achieved by the introduction of a glycine–serine linker in position 24, carrying a C18 di-acid[1].
Survodutide (BI 456906
3, 10, 20, 30 nmol/kg
SC
daily
30 days) achieves a greater bodyweight-lowering efficacy in diet-induced obese mice compared with maximally effective doses of Semaglutide (HY-114118
20, 100 nmol/kg). Survodutide dose-dependently reduces plasma glucagon[1]. Survodutide (1, 3, 10, 30, 100 nmol/kg
SC
single dose) dose-dependently reducesacute food intake in WT but not in GLP-1R KO mice (Three-week-old, male, lean NMRI outbred mice)[1]. Survodutide (1, 3, 10, 30, 100 nmol/kg
SC
single dose) engages the glucagon receptor in vivo upon single dosing, increases liver nicotinamide N-methyltransferase mRNA, and reduces plasma serine and glutamine[1]. Survodutide (SC injection) causes mean residence times of 44 and 140 h and Tmax values of 7 and 51 h obtained in mice and dogs, respectively[1]. Pharmacokinetic Parameters of Survodutide (BI 456906) in mice and dogs[1]. Mice (20 nmol/kg
SC) Dogs (10 nmol/kg
SC) Tmax (h) 7 50.7 Cmax (nM) 84.9 62.0 AUC0-∞ (nM∗h) 4640 9540
| | | |
| | | | | |
[1]. Tina Zimmermann, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022 Dec:66:101633. [Content Brief]